Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
•
HIV & AIDS
Would you consider using thalidomide for treating HIV-associated tuberculosis-IRIS in adult patients who have poor response or intolerance to corticosteroid therapy?
Related Questions
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
What do you prescribe for HIV post-exposure prophylaxis in patients who cannot swallow tablets and have no enteral tube?
How do you approach the treatment of H. pylori infection in people living with HIV, considering the increased risk of antibiotic resistance and potential drug interactions with antiretroviral therapy?
What patient factors influence your decision between prescribing oral pre-exposure prophylaxis and long-acting injectable PrEP for HIV prevention?
Do you recommend to continue acyclovir to prevent HSV infection in an HIV patient with CD4 count more than 200 and with high viral load?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
Would you use immunotherapy in patients with HIV and a positive viral load?
How would you approach using pyrazinamide to treat active pulmonary tuberculosis in an East Asian patient with a history of gout, with a uric acid level of 9.5 mg/dl who is not on allopurinol?
How do you balance diagnostic stewardship and high value cost-conscious care when working up a patient with newly diagnosed HIV/AIDS admitted to the ICU with shortness of breath who most likely has PJP pneumonia or cryptococcal infection but is at risk of multiple other pathogens?
Would you consider adding azithromycin to standard antituberculosis treatment to reduce inflammation and tissue damage in patients with pulmonary tuberculosis?
